We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current ASCLF market cap is 944.4M. The company's latest EPS is CNY -0.2971 and P/E is -3.13.
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| CNY (元) | CNY (元) | CNY (元) | CNY (元) | CNY (元) | |
| Total Revenue | 35M | 76.88M | 54.09M | 56.6M | 1.28M |
| Operating Income | -173.99M | -199.71M | -422.35M | -322.52M | -423.87M |
| Net Income | -209.24M | -199.02M | -314.84M | -144.72M | -300.94M |
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| CNY (元) | CNY (元) | CNY (元) | CNY (元) | CNY (元) | |
| Total Assets | 3.07B | 2.83B | 2.66B | 2.49B | 2.12B |
| Total Liabilities | 85.42M | 100.89M | 117.16M | 148.94M | 158.41M |
| Total Equity | 2.98B | 2.73B | 2.54B | 2.34B | 1.97B |
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| CNY (元) | CNY (元) | CNY (元) | CNY (元) | CNY (元) | |
| Operating | -84.91M | -146.93M | -142.45M | -144.16M | -220.52M |
| Investing | 132.3M | -274.49M | -1.3B | 149.85M | 857.85M |
| Financing | -21.67M | -31.1M | -1.42M | -81.5M | -103.51M |
| Market Cap | 944.4M |
| Price to Earnings Ratio | -3.13 |
| Price to Sales Ratio | 715.38 |
| Price to Cash Ratio | 1.09 |
| Price to Book Ratio | 0.48 |
| Dividend Yield | - |
| Shares Outstanding | 1.01B |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 500 |
| 52 Week Change | 565.12% |
| 52 Week High | 1.20 |
| 52 Week Low | 0.1402 |
| Spread (Intraday) | 0.61 (39.1%) |
| Company Name | Ascletis Pharma Inc (PK) |
| Address |
walkers corporate limited grand cayman KY1-9008 |
| Website | https://www.ascletis.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
